Skip to main content
Premium Trial:

Request an Annual Quote

Sirna, Sigma-Aldrich, Rubicon, CombiMatrix


Sirna to Release Q4, FY 2005 Financials on March 1

Sirna Therapeutics said this week that it will release its fourth-quarter and full-year 2005 financial results on March 1.

The company also said it will hold a conference call to discuss the results at 4:30 pm EST on March 1.

A live webcast of the call can be accessed on Sirna's corporate website.

Sigma-Aldrich to Offer Rubicon's Genome Amplification Kits

Sigma-Aldrich said last week that it has signed a licensing deal allowing it to offer Rubicon Genomics' GenomePlex Whole Genome Amplification kits to service providers.

Rubicon Genomics will retain all rights to the kits for molecular diagnostics, and will continue its existing service business, Sigma-Aldrich said.

Additional terms of the arrangement were not disclosed.

CombiMatrix Shares Climb 6.6 Percent on Strong Q4 Revenue Growth

CombiMatrix this week reported fourth-quarter revenues of $3.6 million versus $522,000 in the year-ago period.

Total receipts for the period included $2.3 million in previously deferred revenues recognized from CombiMatrix's completion of its R&D agreement with Toppan Printing.

R&D costs increased 25 percent to $1.7 million from $1.4 million in the year-ago period.

Net losses in the fourth quarter narrowed 57 percent to $1.8 million from $4.1 million, CombiMatrix said.

The unit had around $20.2 million in cash and short-term investments as of Dec.31.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.